Clinical Working Party

November 2023: Management of CGD in the 21st Century

Home/ Working Parties/ Clinical Working Party/ Grand Rounds 2021-2024/ November 2023: Management of CGD in the 21st Century

ESID Grand Rounds Webinar Nov2023_Zoom

Date: Thursday, 16 November 2023 (17:00 CET/ 16:00 GMT)

Please click here to view the webinar video.

Topic: The Management of CGD in the 21st Century.


This session will be hosted by Dr. Andrew Gennery.

During this session of the Grand Rounds, we will explore the topic, "Management of CGD in the 21st Century."

The schedule of presentations is as follows:

  1. Andrew Gennery: Introduction
  2. David Lowe: Medical Management of CGD (20 minutes)
  3. Mary Slatter: Haematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (20 minutes)
  4. Claire Booth: Gene Therapy for CGD (20 minutes)
  5. Panel discussion


Andrew Gennery_moderator

Prof. Andrew Gennery (moderator)
Honorary Consultant in Paediatric Immunology and Haematopoietic Stem Cell Transplantation at the Faculty of Medical Sciences, Newcastle University (United Kingdom).

David Lowe_new-min

Dr. David Lowe (speaker)
Consultant Clinical Immunologist at the Royal Free London NHS Foundation Trust, London (United Kingdom).

Mary Slatter

Prof. Mary Slatter (speaker)
Clinical Leadership Consultant in & Clinical Programme Director - Paediatric HSCT at the Great North Children's Haematopoietic Stem Cell Transplantation (HSCT) Unit, Newcastle upon Tyne (United Kingdom).

Claire Booth

Prof. Claire Booth (speaker)
Consultant Paediatric Immunologist at UCL Great Ormond Street Institute of Child Health/Great Ormond Street Hospital, London (United Kingdom).

The 2023 ESID Grand Rounds are supported by the Barcelona PID foundation:

BCN logo 165x200_FINAL ZOOM LOGO

"The Barcelona PID Foundation is a non-profit organization founded in 2014 by patients and healthcare professionals. We work to provide support and resources to patients with PID and their
families, to increase awareness of these rare diseases among non-immunologists and the general public, and to promote high-quality research in this field."